Low-Dose Atropine 0.025% for Childhood Myopia Control: A Retrospective Review in Clinical Practice
Journal of Clinical Medicine · 04.11.2026 · 15 (21) · 8587
DOI: 10.3390/jcm15218587 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 04.11.2026. Verfasst von Ng Kaiwen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ministry of Health Holdings Private Limited (MOHH), Singapore 139691, Singapore. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim
In this retrospective audit, Atropine 0.025% eyedrops were evaluated in a clinical setting.
Method
Children aged 4–16 years, who were started on Atropine 0.025% with at least 6 months of follow-up, were included. A total of 588 eyes (299 children) were classified as treatment-naïve eyes started on Atropine 0.025% daily (Group A, n146), eyes progressing on Atropine 0.01% daily increased to 0.025% daily (Group B, n287) or combined with myopia control glasses (Group C, n66), and those stable on Atropine 0.01% twice daily converted to Atropine 0.025% daily (Group D, n89). Spherical equivalent (SE) and axial length (AL) were recorded from 6 months before treatment to 24 months after treatment began.
Result
Group A children were younger (8.4 ± 1.5 years), while Group D children were older (10.6 ± 1.59 years). Progression in the first 6 m was significantly less than that in 6 m prior in Groups A-C. At 1 year, a change in AL < 0.15 mm was noted in 41%, 49%, 50% and 35%, and a change in AL ≥ 0.30 mm was observed in 38%, 18%, 32% and 23% of eyes in Groups A, B, C and D, respectively. Treatment was increased in 37%, 34%, 12% and 41% of eyes over 2 years in Groups A, B, C and D, respectively. Mean progression at 2 years was −0.63 ± 0.86 D or 0.44 ± 0.31 mm, −0.39 ± 0.59 D or 0.30 ± 0.26 mm, −0.30 ± 0.48 D or 0.36 ± 0.40 mm, and −0.48 ± 0.54 D or 0.33 ± 0.22 mm in Groups A, B, C and D, respectively. Multivariate analysis suggested that progression was mainly associated with younger age.
Conclusions
Atropine 0.025% was a useful addition to myopia control, with some eyes requiring further modification in treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ministry of Health Holdings Private Limited (MOHH), Singapore 139691, Singapore.
- Singapore National Eye Centre (SNEC), Singapore 168751, Singapore.
- Myopia Centre at Bedok, Singapore 460212, Singapore.
- Singapore Eye Research Institute (SERI), Singapore 169856, Singapore.
ORCID-Profile: Aaron Qi Yang Goh
Zitieren
APA
Kaiwen, N., Goh, A. Q. Y., Sim, B. X., Yudah, S., Chan, P. P. L., Htoon, H. M., & Chia, A. W. L. (2026). Low-Dose Atropine 0.025% for Childhood Myopia Control: A Retrospective Review in Clinical Practice. Journal of Clinical Medicine, 15(21), 8587. https://doi.org/10.3390/jcm15218587
Vancouver
Kaiwen N, Goh AQY, Sim BX, Yudah S, Chan PPL, Htoon HM, et al. Low-Dose Atropine 0.025% for Childhood Myopia Control: A Retrospective Review in Clinical Practice. Journal of Clinical Medicine. 2026;15(21):8587. doi:10.3390/jcm15218587
BibTeX
@article{Kaiwen2026,
author = {Kaiwen, Ng and Goh, Aaron Qi Yang and Sim, Bryan Xiangrong and Yudah, Sri and Chan, Pauline Poh Lin and Htoon, Hla Myint and Chia, Audrey Wei Lin},
title = {Low-Dose Atropine 0.025% for Childhood Myopia Control: A Retrospective Review in Clinical Practice},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {21},
pages = {8587},
doi = {10.3390/jcm15218587}
}
EUVIMED